113 related articles for article (PubMed ID: 28866467)
1. CTA1: Purified and display onto gram-positive enhancer matrix (GEM) particles as mucosal adjuvant.
Zhang Y; Yu X; Hou L; Chen J; Li P; Qiao X; Zheng Q; Hou J
Protein Expr Purif; 2018 Jan; 141():19-24. PubMed ID: 28866467
[TBL] [Abstract][Full Text] [Related]
2. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit.
Agren L; Löwenadler B; Lycke N
Immunol Cell Biol; 1998 Jun; 76(3):280-7. PubMed ID: 9682972
[TBL] [Abstract][Full Text] [Related]
3. Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes.
Chowdhury MYE; Kim TH; Uddin MB; Kim JH; Hewawaduge CY; Ferdowshi Z; Sung MH; Kim CJ; Lee JS
Vet Microbiol; 2017 Mar; 201():240-251. PubMed ID: 28284616
[TBL] [Abstract][Full Text] [Related]
4. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
[TBL] [Abstract][Full Text] [Related]
5. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
[TBL] [Abstract][Full Text] [Related]
6. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
Lycke N
Cell Microbiol; 2004 Jan; 6(1):23-32. PubMed ID: 14678328
[TBL] [Abstract][Full Text] [Related]
7. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria.
van Roosmalen ML; Kanninga R; El Khattabi M; Neef J; Audouy S; Bosma T; Kuipers A; Post E; Steen A; Kok J; Buist G; Kuipers OP; Robillard G; Leenhouts K
Methods; 2006 Feb; 38(2):144-9. PubMed ID: 16414272
[TBL] [Abstract][Full Text] [Related]
8. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
Agren LC; Ekman L; Löwenadler B; Nedrud JG; Lycke NY
J Immunol; 1999 Feb; 162(4):2432-40. PubMed ID: 9973526
[TBL] [Abstract][Full Text] [Related]
9. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
Agren LC; Ekman L; Löwenadler B; Lycke NY
J Immunol; 1997 Apr; 158(8):3936-46. PubMed ID: 9103464
[TBL] [Abstract][Full Text] [Related]
10. The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses.
Bagley K; Xu R; Ota-Setlik A; Egan M; Schwartz J; Fouts T
Hum Vaccin Immunother; 2015; 11(9):2228-40. PubMed ID: 26042527
[TBL] [Abstract][Full Text] [Related]
11. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.
Fang Y; Larsson L; Mattsson J; Lycke N; Xiang Z
J Immunol; 2010 Sep; 185(5):2935-41. PubMed ID: 20675596
[TBL] [Abstract][Full Text] [Related]
12. Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae.
Lebens M; Terrinoni M; Karlsson SL; Larena M; Gustafsson-Hedberg T; Källgård S; Nygren E; Holmgren J
Vaccine; 2016 Apr; 34(18):2121-8. PubMed ID: 26973069
[TBL] [Abstract][Full Text] [Related]
13. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells.
Helgeby A; Robson NC; Donachie AM; Beackock-Sharp H; Lövgren K; Schön K; Mowat A; Lycke NY
J Immunol; 2006 Mar; 176(6):3697-706. PubMed ID: 16517738
[TBL] [Abstract][Full Text] [Related]
14. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
Mowat AM; Donachie AM; Jägewall S; Schön K; Löwenadler B; Dalsgaard K; Kaastrup P; Lycke N
J Immunol; 2001 Sep; 167(6):3398-405. PubMed ID: 11544331
[TBL] [Abstract][Full Text] [Related]
15. Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction Domain.
Shim BS; Cheon IS; Lee E; Park SM; Choi Y; Jung DI; Yang E; Choi JA; Chun JY; Kim JO; Yun CH; Czerkinsky C; Song MK
J Immunol Res; 2018; 2018():9830701. PubMed ID: 29707588
[TBL] [Abstract][Full Text] [Related]
16. Intranasal Immunization Using CTA1-DD as a Mucosal Adjuvant for an Inactivated Influenza Vaccine.
Fan XT; Wang YL; Su QD; Qiu F; Yi Y; Jia ZY; Wang DY; Qin K; Zou YN; Bi SL; Shen LP
Biomed Environ Sci; 2019 Jul; 32(7):531-540. PubMed ID: 31331437
[TBL] [Abstract][Full Text] [Related]
17. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
De Filette M; Ramne A; Birkett A; Lycke N; Löwenadler B; Min Jou W; Saelens X; Fiers W
Vaccine; 2006 Jan; 24(5):544-51. PubMed ID: 16169634
[TBL] [Abstract][Full Text] [Related]
18. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
19. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
Saluja V; Visser MR; Ter Veer W; van Roosmalen ML; Leenhouts K; Hinrichs WL; Huckriede A; Frijlink HW
Vaccine; 2010 Nov; 28(50):7963-9. PubMed ID: 20946860
[TBL] [Abstract][Full Text] [Related]
20. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
Lycke N
Ann N Y Acad Sci; 2004 Dec; 1029():193-208. PubMed ID: 15681758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
